Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
- Conditions
- Pancreatic Adenocarcinoma ResectablePancreatic CancerPancreas CancerPancreatic Ductal AdenocarcinomaPancreas Metastases
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 27
- Registration Number
- NCT03410030
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
- Conditions
- Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 129
- Registration Number
- NCT03410615
- Locations
- 🇧🇪
University Hospital of Gent, Gent, Belgium
🇧🇪AZ Sint Augustinus, Wilrijk, Belgium
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Biliary Tract Neoplasms
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 92
- Registration Number
- NCT03406299
- Locations
- 🇨🇳
Taiwan Cooperative Oncology Group, National Health Research Institutes, Taipei, Taiwan
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: PalbociclibDrug: CisplatinDrug: CetuximabRadiation: Intensity-Modulated Radiation TherapyProcedure: Tumor biopsyProcedure: Peripheral blood draw
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT03389477
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
- Conditions
- Oral Mucositis (Ulcerative) Due to Radiation
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 176
- Registration Number
- NCT03387774
- Locations
- 🇨🇳
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03387943
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Drug: Aldoxorubicin HClBiological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionDrug: AvelumabDrug: bevacizumabDrug: CapecitabineDrug: CetuximabDrug: CisplatinDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: NecitumumabProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Aldoxorubicin HClBiological: N-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for InfusionBiological: avelumabBiological: bevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03387085
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: NivolumabBiological: CetuximabDrug: BMS-986205Drug: CisplatinDrug: CarboplatinDrug: Fluorouracil
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03386838
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03382600
- Locations
- 🇯🇵
Kanagawa Cancer Center ( Site 0003), Yokohama, Kanagawa, Japan
🇯🇵Chiba Cancer Center ( Site 0012), Chiba, Japan
🇯🇵National Hospital Organization Shikoku Cancer Center ( Site 0024), Matsuyama, Ehime, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.